Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 269605, 9 pages
http://dx.doi.org/10.1155/2014/269605
Review Article

Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?

1Imanova Ltd., Centre for Imaging Sciences, Imperial College Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
2GlaxoSmithKline Global Imaging Unit, Stockley Park West, 1-3 Ironbridge Road, Uxbridge, Middlesex UB11 1BT, UK
3Early Phase Oncology Clinical Investigation, Eli Lilly Corporate Center, Building 31/4, 893 S. Delaware Street, Indianapolis, IN 46285, USA

Received 6 June 2014; Accepted 18 July 2014; Published 18 August 2014

Academic Editor: Masahiro Ono

Copyright © 2014 Azeem Saleem et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Azeem Saleem, Philip Murphy, Christophe Plisson, and Michael Lahn, “Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?,” The Scientific World Journal, vol. 2014, Article ID 269605, 9 pages, 2014. https://doi.org/10.1155/2014/269605.